<DOC>
	<DOCNO>NCT00078065</DOCNO>
	<brief_summary>This trial phase II , randomize study patient multiple myeloma . All patient receive Xcellerated T Cells , without prior fludarabine therapy . 15 patient study arm follow 6 month .</brief_summary>
	<brief_title>Xcellerated T CellsTM Patients With Multiple Myeloma</brief_title>
	<detailed_description>This randomized Phase II clinical study design examine safety efficacy Xcellerated T CellsTM , activate , autologous T cell product , subject multiple myeloma . Subjects must fail least one , three , prior cytotoxic therapy prior study registration may relapse progress within one year follow hematopoietic stem cell transplantation . Patients randomize treatment either Xcellerated T Cells alone , lymphoablative therapy fludarabine follow Xcellerated T Cells . Thirty subject treat , 15 patient arm . Patients follow six month follow treatment .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Previous diagnosis multiple myeloma ( MM ) base standard criterion . Tests need perform within 30 day registration . Failure least one , four , prior systemic therapy MM prior registration may relapse progress within 1 year follow autologous hematopoietic stem cell transplantation . Repeat course therapeutic regimen separate time 6 month consider separate therapy . Induction therapy follow high dose chemotherapy autologous hematopoietic stem cell transplantation count one therapy . Measurable serum and/or urine Mprotein Disease progression relapse , since recent therapy multiple myeloma Age &gt; 18 year old &lt; 75 year old ECOG performance status 0 1 Females childbearing potential must negative serum bHCG test willing use effective contraception ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration trial Negative test result current/active infection HIV1 , HIV2 , HTLV1 , HTLV2 , hepatitis B , hepatitis C within 30 day registration ( Antibody , antigen , nucleic acid test acceptable , depend institutional standard ) Hemoglobin &gt; = 10.0 g/dL . Transfusion red blood cell use erythropoietin permissible . White blood count ( WBC ) &gt; = 3,000/mm3 absolute neutrophil count ( ANC ) &gt; 1000/mm3 Platelet count &gt; 75,000/mm3 Corrected serum calcium &lt; 11 mg/dL , evidence symptomatic hypercalcemia . ( Corrected serum calcium calculate add 0.8 mg/dL measure serum calcium every 1 g/dL serum albumin fall 4.0 g/dL ) Serum total bilirubin alanine aminotransferase ( ALT ) &lt; 2.0 time upper limit normal Serum creatinine &lt; 2.5 mg/dL Serum human antimouse antibody ( HAMA ) titer undetectable within normal range , history allergy mice murine ( mouse ) proteins The patient must able comprehend sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>fludarabine</keyword>
	<keyword>Xcellerated T Cells</keyword>
</DOC>